Evidence map›Paper›PMID 26001081›Full record

ArticlePLoS pathogens2015

Activation of Salmonella Typhi-specific regulatory T cells in typhoid disease in a wild-type S. Typhi challenge model.

Monica A McArthur, Stephanie Fresnay, Laurence S Magder, Thomas C Darton, Claire Jones, Claire S Waddington, Christoph J Blohmke, Gordon Dougan, Brian Angus, Myron M Levine and 2 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in PLoS pathogens, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 51 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Antigen-specific TScience advances · 2026
    Article
  7. Broad systemic T cell immunity toFrontiers in immunology · 2026
    Article
  8. Distinct time-dependentFrontiers in cellular and infection microbiology · 2026
    Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Revisiting PersistentPathogens (Basel, Switzerland) · 2021
    Review
  14. Review
  15. Article
  16. Article
  17. HumanClinical & translational immunology · 2020
    Article
  18. Frontiers in cellular and infection microbiology · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Monica A McArthurCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Stephanie FresnayCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Laurence S MagderDepartment of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Thomas C DartonOxford Vaccine Group, Department of Paediatrics, University of Oxford and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford, United Kingdom.
Claire JonesOxford Vaccine Group, Department of Paediatrics, University of Oxford and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford, United Kingdom.
Claire S WaddingtonOxford Vaccine Group, Department of Paediatrics, University of Oxford and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford, United Kingdom.
Christoph J BlohmkeOxford Vaccine Group, Department of Paediatrics, University of Oxford and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford, United Kingdom.
Gordon DouganMicrobial Pathogenesis Group, Wellcome Trust Sanger Institute, Hinxton, United Kingdom.
Brian AngusNuffield Department of Medicine, University of Oxford, United Kingdom.
Myron M LevineCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
Andrew J PollardOxford Vaccine Group, Department of Paediatrics, University of Oxford and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford, United Kingdom.
Marcelo B SzteinCenter for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
University of Maryland, Baltimore · USNational Institute for Health Research · GBUniversity of Oxford · GBWellcome Sanger Institute · GB

Funding

Wild-type S. typhi Infection in Humans: Integrated Immunoprotective MechanismsU19AI082655 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SZTEIN, MARCELO B. · 2009 to 2018
$27.8M
Shigella Live Vector-Based Multivalent VaccineU19AI109776 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI TZIPORI, SAUL R · 2014 to 2018
$25.4M
IMMUNE MECHANISMS OF PROTECTION IN S TYPHI VACCINESR01AI036525 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Marcelo B. Sztein · 1994 to 2026
$12.2M
FELLOWSHIP TRAINING PROGRAM IN VACCINOLOGYT32AI007524 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Marcelo B. Sztein · 1997 to 2026
$6.4M
NIAID NIH HHS R01 AI036525NIAID NIH HHS R01-AI036525NIAID NIH HHS T32 AI007524NIAID NIH HHS T32-AI07524NIAID NIH HHS U19 AI082655NIAID NIH HHS U19 AI109776NIAID NIH HHS U19-AI109776Wellcome TrustWellcome Trust 092661
6 · The paper itself

Abstract

Salmonella Typhi (S. Typhi), the causative agent of typhoid fever, causes significant morbidity and mortality worldwide. Currently available vaccines are moderately efficacious, and identification of immunological responses associated with protection or disease will facilitate the development of improved vaccines. We investigated S. Typhi-specific modulation of activation and homing potential of circulating regulatory T cells (Treg) by flow and mass cytometry using specimens obtained from a human challenge study. Peripheral blood mononuclear cells were obtained from volunteers pre- and at multiple time-points post-challenge with wild-type S. Typhi. We identified differing patterns of S. Typhi-specific modulation of the homing potential of circulating Treg between volunteers diagnosed with typhoid (TD) and those who were not (No TD). TD volunteers demonstrated up-regulation of the gut homing molecule integrin α4ß7 pre-challenge, followed by a significant down-regulation post-challenge consistent with Treg homing to the gut. Additionally, S. Typhi-specific Treg from TD volunteers exhibited up-regulation of activation molecules post-challenge (e.g., HLA-DR, LFA-1). We further demonstrate that depletion of Treg results in increased S. Typhi-specific cytokine production by CD8+ TEM in vitro. These results suggest that the tissue distribution of activated Treg, their characteristics and activation status may play a pivotal role in typhoid fever, possibly through suppression of S. Typhi-specific effector T cell responses. These studies provide important novel insights into the regulation of immune responses that are likely to be critical in protection against typhoid and other enteric infectious diseases.

Indexed as

Models, BiologicalAdolescentAdultCase-Control StudiesCD8-Positive T-LymphocytesFlow CytometryHumansLeukocytes, MononuclearMass SpectrometryMiddle AgedSalmonella typhiT-Lymphocytes, CytotoxicT-Lymphocytes, RegulatoryTyphoid FeverYoung Adult

Identifiers

PMID26001081
PMCPMC4441490
OpenAlexW1540445377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.